sales@jinjingroup.com

  News Introduction

Phenylpiracetam(cas 77472-70-9), tracking the therapy

Date : 2016/9/14 10:52:12

At present, when using phenylpiracetam(cas 77472-70-9) therapy, clinical problem facing that doctors did not discuss in detail with the patients and their families to benefit patients with limited delay of progression or mild improvement of the disease, is still not completely reverse or cure the disease, resulting in many patients in the medication after 2 to 3 months because of feeling less than treatment discontinued, so that the disease gradually increased. Therefore, clinicians should expect to benefit patients and their families account for drug therapy, in order to ensure long-term treatment.

Note phenylpiracetam (cas 77472-70-9) adverse reactions, in addition, APA guidelines remind doctors applying AChEI, due to the acetylcholine (ACh) peripheral M cholinergic receptor have lower blood pressure, heart rate, increase the role of glandular secretion , with sick sinus syndrome or severe atrioventricular block, acute gastritis, gastric ulcer, asthma or severe chronic obstructive pulmonary disease patients should be used with caution. ACh produced using some of the more minor side effects such as dizziness, nausea in 2 ~ 4 d after treatment will gradually reduce as the patient can tolerate the medication first few days of discomfort, subsequent treatment may no symptoms.

Adhere to follow-up the efficacy of phenylpiracetam (cas 77472-70-9): EFNS guidelines recommend at least every 3 to 6 months follow-up 1, to evaluate the treatment, such as ease of use Mental State Examination (MMSE), to Based on the assessment of the adjustment of drug dose and treatment programs to ensure the effectiveness of efficacy.